Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAAST: Vildagliptin/Metformin in Diabetic CAD
NCT01604213Phase 4Completed
- Sponsor
- Sheba Medical Center
- Start
- Sep 2012
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sheba Medical Center. Primary endpoint: Interleukin 6 at 3 months. Started Sep 2012; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01604213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604213.